1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile

Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H, Bode W, GomisRuth FX (1997)
EUROPEAN JOURNAL OF BIOCHEMISTRY 247(1): 356-363.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ;
Abstract
Matrix metalloproteinases (MMP) are zinc endopeptidases involved in tissue remodelling. They have been implicated in a series of pathologies, including cancer, arthritis, joint destruction and Alzheimer's disease. Human neutrophil collagenase represents one of the three interstitial collagenases that cleave triple-helical collagen of type I, II and III. Its catalytic domain (residues Phe79-Gly242) has been heterologously expressed in Escherichia coli and crystallized as a non-covalent complex with the hydroxamate inhibitor BB-1909, which has distinct selectivity against different MMP, in a crystal form. The crystal structure, refined to 0.18-nm resolution, shows that BB-1909 is a right-hand-side inhibitor that binds to the S-1'-S-3' subsites and coordinates to the catalytic Zn2+ in a bidentate manner via the hydroxyl and carbonyl oxygen atoms of the hydroxamate group in a similar manner to batimastat. The collagenase/BB-1909 complex is described in detail and compared with the collagenase/batimastat complex. These studies provide information on MMP specificity and thus may assist the development of more-selective MMP inhibitors.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Betz M, Huxley P, Davies SJ, et al. 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY. 1997;247(1):356-363.
Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., et al. (1997). 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY, 247(1), 356-363.
Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., and GomisRuth, F. X. (1997). 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY 247, 356-363.
Betz, M., et al., 1997. 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY, 247(1), p 356-363.
M. Betz, et al., “1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile”, EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 247, 1997, pp. 356-363.
Betz, M., Huxley, P., Davies, S.J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., GomisRuth, F.X.: 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY. 247, 356-363 (1997).
Betz, M, Huxley, P, Davies, SJ, Mushtaq, Y, Pieper, M, Tschesche, Harald, Bode, W, and GomisRuth, FX. “1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile”. EUROPEAN JOURNAL OF BIOCHEMISTRY 247.1 (1997): 356-363.
This data publication is cited in the following publications:
This publication cites the following data publications:

25 Citations in Europe PMC

Data provided by Europe PubMed Central.

Targeting angiogenesis for treatment of human cancer.
Somani RR, Bhanushali UV., Indian J Pharm Sci 75(1), 2013
PMID: 23901154
Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2).
Higashi S, Hirose T, Takeuchi T, Miyazaki K., J. Biol. Chem. 288(13), 2013
PMID: 23395821
Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
Chaudhary AK, Pandya S, Ghosh K, Nadkarni A., Mutat. Res. 753(1), 2013
PMID: 23370482
Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases.
Geng L, Gao J, Cui W, Tang Y, Ji M, Chen B., J. Comput. Aided Mol. Des. 26(12), 2012
PMID: 23224743
Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J, Itzhaki O, Huszar M, Sinai J., Immunotherapy 3(11), 2011
PMID: 22053888
Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.
Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S., J. Biol. Chem. 286(38), 2011
PMID: 21813640
The structure of the catalytic domain of Tannerella forsythia karilysin reveals it is a bacterial xenologue of animal matrix metalloproteinases.
Cerda-Costa N, Guevara T, Karim AY, Ksiazek M, Nguyen KA, Arolas JL, Potempa J, Gomis-Ruth FX., Mol. Microbiol. 79(1), 2011
PMID: 21166898
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C, Theocharis AD, Karamanos NK., FEBS J. 278(1), 2011
PMID: 21087457
Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma.
Lyons AJ, Jones J., Int J Oral Maxillofac Surg 36(8), 2007
PMID: 17643963
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E., Bioorg. Med. Chem. 15(14), 2007
PMID: 17512742
Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V., Biochimie 87(3-4), 2005
PMID: 15781327
Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2.
Ouellet M, Aitken SM, English AM, Percival MD., Arch. Biochem. Biophys. 431(1), 2004
PMID: 15464732
Matrix metalloproteinase inhibitors.
Ramnath N, Creaven PJ., Curr Oncol Rep 6(2), 2004
PMID: 14751086
Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.
Morales R, Perrier S, Florent JM, Beltra J, Dufour S, De Mendez I, Manceau P, Tertre A, Moreau F, Compere D, Dublanchet AC, O'Gara M., J. Mol. Biol. 341(4), 2004
PMID: 15289103
Development of matrix metalloproteinase inhibitors in cancer therapy.
Purcell WT, Rudek MA, Hidalgo M., Hematol. Oncol. Clin. North Am. 16(5), 2002
PMID: 12512389
Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M, Eckhardt SG., J. Natl. Cancer Inst. 93(3), 2001
PMID: 11158186
Ongoing trials with matrix metalloproteinase inhibitors.
Brown PD., Expert Opin Investig Drugs 9(9), 2000
PMID: 11060801
High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Levin JI, Powers R., J. Mol. Biol. 302(3), 2000
PMID: 10986126
Matrix metalloproteases: variations on a theme.
Borkakoti N., Prog. Biophys. Mol. Biol. 70(1), 1998
PMID: 9785958

41 References

Data provided by Europe PubMed Central.

The origin of matrix metalloproteinases and their familial relationships.
Murphy GJ, Murphy G, Reynolds JJ., FEBS Lett. 289(1), 1991
PMID: 1894005
The matrix metalloproteinases and their inhibitors.
Murphy G, Docherty AJ., Am. J. Respir. Cell Mol. Biol. 7(2), 1992
PMID: 1497900

Murphy, J. Rheumatol. 19(), 1992

AUTHOR UNKNOWN, 0
Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain.
Peress N, Perillo E, Zucker S., J. Neuropathol. Exp. Neurol. 54(1), 1995
PMID: 7815076
Structural implications for the role of the N terminus in the 'superactivation' of collagenases. A crystallographic study.
Reinemer P, Grams F, Huber R, Kleine T, Schnierer S, Piper M, Tschesche H, Bode W., FEBS Lett. 338(2), 1994
PMID: 8307185
The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity.
Schnierer S, Kleine T, Gote T, Hillemann A, Knauper V, Tschesche H., Biochem. Biophys. Res. Commun. 191(2), 1993
PMID: 8460992

Spurlino, Proteins, Struct. Funct. Genet. 19(), 1994

Stams, Nat. Struct. Biol. (), 1994

Stetler-Stevenson, J. Biol. Chem. 29(), 1989
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis.
Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr., FASEB J. 7(15), 1993
PMID: 8262328
Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family.
Uria JA, Ferrando AA, Velasco G, Freije JM, Lopez-Otin C., Cancer Res. 54(8), 1994
PMID: 8174111
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.
Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E., J. Rheumatol. 23(4), 1996
PMID: 8730110
Structure-function relationships in the tissue inhibitors of metalloproteinases.
Willenbrock F, Murphy G., Am. J. Respir. Crit. Care Med. 150(6 Pt 2), 1994
PMID: 7952654

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 9249047
PubMed | Europe PMC

Search this title in

Google Scholar